The UK and US have announced a key trade agreement that will keep zero import taxes on UK medicine exports being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to increase expenditure on drugs through the National Health Service (NHS). This commitment ensures that import taxes on these key products will be held at nothing for a period of the next three years.
This development comes after previous statements to significantly raise tariffs on patented pharmaceutical imports, with potential rates discussed up to 100%.
"This deal between the Britain strengthens the worldwide climate for innovative medicines and introduces long-overdue balance to U.S.–U.K. medicine commerce," a statement said.
Economic Impact
Medicines are one of the UK's largest export categories to the America, which is by far the primary market for leading companies like GSK and AstraZeneca.
Statistics show that in the one-year period to the end of last September, the UK exported medicines valued at billions to the US. This figure represented 17.4% of all goods exports in that span.
"This guarantee safeguards work, boosts funding and facilitates the UK to become a global hub for biotech and pharma," a minister stated.
Specific British Pledges
The agreement involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to double total NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum manufacturers must refund to the NHS to prevent overspending will be limited at 15%. In the past, repayments topped 20%.
Recent Tensions
The deal follows a ongoing dispute between the drug companies and the UK government over spending levels and NHS adoption.
The disagreement were intensified by claims that American consumers were paying a premium for the same drugs than consumers in the Britain and the EU.
Recently, several significant manufacturing plans in the UK have been paused or abandoned, while multi-billion-dollar investments have been directed toward projects in the United States.
One official acknowledged that the NHS must spend more on treatments, noting that its expenditure on drugs had decreased as a proportion of its total funding over the past decade.
